Eris Lifesciences to buy balance 30 percent stake in Swiss Parenterals for Rs 423 crore
Mumbai: Eris Lifesciences Limited has announced that its Board of Directors has approved the acquisition of the balance 30 percent stake in Swiss Parenterals Limited for Rs 423.3 crore, making swiss a wholly owned subsidiary. Currently Eris holds a 70 percent stake in Swiss.
The proposed transaction will be effected as a share swap, i.e. through a preferential issuance of Eris equity shares to the seller Naishadh Shah, who is also a Director of Swiss and consequently a related party of Swiss, thereby making him a Top-10 shareholder of Eris and an integral part of Eris’ senior management team with long-term alignment.
The acquisition aims to strengthen operational synergies, improve cost efficiencies, and give Eris full control over Swiss.
The proposed transaction is expected to complete tentatively prior to March 31, 2026.
Commenting on the acquisition, Amit Bakshi, Chairman & Managing Director of Eris Lifesciences Ltd, said, ”On behalf of the shareholders of Eris, I am delighted to welcome Naishadh Shah to the community of Erisians. I am also happy to share that we propose to designate him as the Managing Director of Swiss Parenterals. FY27 promises to be a breakout year for our international business and Naishadh’s continued leadership and stewardship will be pivotal to its growth.”
Commenting on the acquisition, Naishadh Shah, Wholetime Director of Swiss Parenterals Ltd, said, ”It is truly exciting to get aligned with Eris as a long-term shareholder and senior management. The Eris platform with its manufacturing capabilities in Ahmedabad and Bhopal, combined with the existing Swiss facilities, will significantly augment our value proposition to our global clientele. I look forward to the next leg of this growth journey.”
